PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Aztreonam”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 415 records · Page 23Linked to original sources
PubMed1987

Amikacin plus ceftazidime versus amikacin plus piperacillin versus amikacin plus aztreonam in infections in neoplastic patients with granulocytopenia.

Sixty granulocytopenic patients (granulocytes less than 1000/mm3) affected with solid tumors, previously submitted to antiblastic therapy and with infections, were treated with three antibiotic combinations: amikacin + ceftazidime, amikacin + piperacillin or amikacin + aztreonam. In 68% of the cases the infections were due to gram-negative and in the remaining 32% to gram-positive microorganisms. The results obtained with the three treatments show a slight but significant statistical difference (p less than 0.05), due to the greater efficacy of the amikacin + ceftazidime combination on gram-positive and amikacin + aztreonam on gram-negative bacteria.

Adult↗
PubMed1987

Comparison trial of clindamycin with aztreonam or gentamicin in the treatment of postpartum endometritis.

Sixty-two patients who had postpartum endometritis were treated with clindamycin in combination with either aztreonam or the aminoglycoside gentamicin. Currently, the combination of clindamycin and an aminoglycoside constitutes a treatment of choice for this condition. Our results suggest that aztreonam can be substituted for an aminoglycoside in the treatment of postpartum endometritis with similar clinical outcomes.

Adolescent↗
PubMedDate not supplied

Determination of aztreonam and L-arginine combination in parenteral formulations.

A rapid, sensitive and precise liquid chromatographic method is presented for the determination of aztreonam alone, in the presence of its degradation product, and in a parenteral formulation containing l-arginine. A reverse phase column and 0.2M phosphate buffer (pH 6)-methanol (95 + 5) with mobile phase at a flow rate of 2 mL/min is used. The method is sensitive for the range of 10-50 micrograms/mL with a relative standard deviation of less than 2%. The method has been applied to a parenteral formulation containing aztreonam and l-arginine. L-Arginine is also determined by a nonaqueous titrimetric method.

Arginine↗
PubMed1986

[Evaluation of the in vitro activity of aztreonam on 1990 gram-negative bacterial strains recently isolated in Campania hospitals].

The in vitro activity of aztreonam, leader of a new class of antibiotics, the monobactams, has been investigated. The effectiveness of the new molecule on 1990 strains of Gram-negative clinical isolates has been compared to that of some other drugs widely utilized for the treatment of nosocomial infections. Aztreonam has shown the highest activity against all the tested strains, with a geometrical mean of MICs (MG) of 0.37 and a MIC 90 of 8 micrograms/ml.

Aztreonam↗
PubMed1987

[In vitro chemo-antibiotic sensitivity of gram-negative bacteria from various biological materials. Comparison between aztreonam and other agents].

527 Gram negative bacterial strains isolated from different biological substances were studied by chemo-antibiotic sensitivity. The examination was carried out by the agar diffusion test (Kirby-Bauer). A very good sensitivity to aztreonam (E. coli, Serratia spp., Klebsiella spp., Proteus spp.), to amikacin (Pseudomonas spp., Enterobacter spp., Citrobacter spp.) and to norfloxacin (Citrobacter spp.) was found. Even when it was not the best, aztreonam was the second (Citrobacter spp.) or the third choice (Pseudomonas spp.), always near to the drug of first choice.

Amikacin↗
PubMed1987

Clinical-experimental research on aztreonam ampullar and ureteral concentrations.

After pointing out that, during urinary tract infections, bacteria can affect the peristalsis of the renal ampulla and of the ureter, the authors report the results of a trial on aztreonam concentrations in the upper urinary tract, performed in order to evaluate the concentrations of the drug in the ampullar and ureteral tissues. This study was carried out on bioptical specimens collected from 18 subjects (12 children and 6 adults), who underwent surgery for malformations of the urinary system. The authors report and discuss the results of the determinations performed on the samples of urinary tract tissue, serum and urine, 60 to 90 minutes after the i.m. administration of aztreonam.

Adolescent↗
PubMed1984

Comparative in vitro activity of aztreonam, other beta-lactam antibiotics and aminoglycosides against Pseudomonas aeruginosa.

Aztreonam, ceftriaxone, moxalactam, cefotaxime, cefsulodin, cefoperazone, piperacillin, azlocillin, carbenicillin, amikacin, gentamicin, tobramycin, sisomicin and dibekacin were tested by broth dilution against 161 isolates of Pseudomonas aeruginosa. Seventy-one of these strains were selected for their resistance to carbenicillin and aminoglycosides and classified as "multiply resistant" strains. Over all, aztreonam showed the greatest antipseudomonal activity by far, followed by ceftriaxone, moxalactam, cefotaxime and amikacin. Piperacillin, azlocillin, cefsulodin, and cefoperazone were highly active against carbenicillin and/or aminoglycoside-susceptible P. aeruginosa strains, but were also poorly inhibitory against multiply resistant isolates.

Aminoglycosides↗
PubMed1984

In vitro study of the sensitivity of 1030 hospital-isolated bacterial strains to aztreonam.

The antibacterial activity in vitro of aztreonam is compared with other antibiotics on 1,030 strains isolated from pathological specimens. Its spectrum is very large, with special regard to Gram-negative bacteria. Of particular interest appears the sensitivity to aztreonam of otherwise multiresistant strains of Pseudomonas aeruginosa and Proteus rettgeri.

Anti-Bacterial Agents↗
PubMed1994

Aztreonam vs. gentamicin in experimental peritonitis and intra-abdominal abscess formation.

The activity of gentamicin is known to be decreased in acidic environments, and both the peritoneum during peritonitis and the interior of abscesses have been shown to be acidic and hypoxic. The activity of beta-lactam antibiotics is felt to be relatively less diminished under the same circumstances. We determined that the minimum inhibitory concentration of gentamicin against one pathogenic strain of Escherichia coli increased eight-fold, to 8 mugm/mL, when testing conditions were changed from normoxic and neutral to hypoxic and acidic, whereas the MIC of aztreonam doubled under the same conditions, to 0.25 mugm/mL. In further experiments in a murine model of mixed Escherichia coli/Bacteroides fragilis intra-abdominal abscesses, we demonstrated that a combination of aztreonam and clindamycin was superior to a combination of gentamicin and clindamycin in terms of completely preventing abscess formation (33% vs. 0%) and eliminating Escherichia coli from abscesses that did form (100% vs. 61%).

Abdominal Abscess↗
PubMedDate not supplied

[Aztreonam--new antibiotic for treating infections caused by gram-negative aerobic bacteria].

Aztreonam is the first synthetic monobactam used in practical medicine. It is effective in Gram-negative aerobe infections. It inhibits the growth of most Enterobacteriaceae in concentrations below 2 mg/ml, and of Pseudomonas aeruginosa below 16 mg/ml. It shows a widespread, distribution achieving effective therapeutic concentration there, where infections are seen most frequently. The half-life is from 1.6 to 2.0 hours. It can be administered to patients every 8 and 12 hours in single parenteral doses of 0.5, 1.0, and 2.0 g. Aztreonam is a non-toxic antibiotic, a weak hapten with slight allergenicity. It has found therapeutic use together with the antibiotics directed against aerobic and anaerobic bacterial Gram-positive flora, and it is used in the therapy directed against infections with Gram-negative aerobes. It is an effective antibiotic in nosocomial infections, in oncological patients with neutropenia, and in elderly patients.

Aged↗
PubMed1993

[Aztreonam as monotherapy in urinary tract infections with a systemic repercussion in patients with a relative contraindication for the use of aminoglycosides].

A comparative study has been performed to evaluate the clinical efficacy and safety of aztreonam in the treatment of urinary tract infections with systemic affectation, in a group of patients who showed a relative contraindication to be treated with aminoglycosides. The group studied was formed by 30 patients (21 females and 9 males). Mean age of said group was 78 years and percentage of patients over 65 years was 93%. Moreover, 53.3% of patients showed nephropathy, 30% diabetes mellitus and 16.6% hearing disorders. Responsible germ of the infection was identified through blood and urine culture in 24 patients (80%) being the most frequent isolated E. Coli (60%). The cure rate was of 76.6% and improvement rate was 13.3%. Three deaths happened on the studied group (10%). In a patient superinfection due to Enterococcus was detected. There were no significative adverse effects (hypersensibility reactions, hematological disorders, nephrotoxicity or hepatotoxicity). Aztreonam could be an efficacious alternative in the treatment of urinary infection with systemic affectation, caused by gram-negative germs, showing low toxicity.

Aged↗
PubMedDate not supplied

Pharmacoeconomics of aztreonam-clindamycin versus gentamicin-clindamycin in the treatment of penetrating abdominal injury.

STUDY OBJECTIVE: To evaluate the pharmacoeconomic implications of using aztreonam-clindamycin (A-C) versus gentamicin-clindamycin (G-C) from the perspective of the hospital and pharmacy directors. DESIGN: Pharmacoeconomic analysis performed at one of the sites participating in the prospective, randomized, double-blind, comparative, multicenter efficacy study. SETTING: Referral hospital with level 1 trauma center. PATIENTS: Eight-five adults with a suspected penetrating intraabdominal injury requiring laparotomy. INTERVENTIONS: Patients were randomized to receive aztreonam 2 g intravenously every 8 hours or gentamicin 2 mg/kg intravenous load followed by 5 mg/kg/day intravenously initially adjusted to peak concentrations of 6-8 micrograms/ml. All patients received clindamycin 900 mg intravenously every 8 hours. MEASUREMENTS AND MAIN RESULTS: Charge data were gathered from the hospital billing system and converted to cost data using an institutional cost:charge ratio of 0.6. Study drug and aminoglycoside monitoring costs were also calculated. Overall, 43 (97%) of 44 patients receiving A-C had a favorable clinical response compared with 35 (85.4%) of 41 receiving G-C (p = 0.052). The mean hospital cost of $66,336 for 7 infected patients was significantly higher than that of $8014 in 78 noninfected patients (p < 0.0001). Mean hospital costs of $12,058 and $13,742 for A-C and G-C groups, respectively, were not significantly different (p > 0.05) despite having only a single failure (total cost $162,666) in the A-C group. Similarly, mean pharmacy costs of $1411 and $1604, respectively, were not significantly different (p > 0.05). CONCLUSIONS: Hospital costs for infected patients with penetrating abdominal trauma exceed those of noninfected patients by 5-fold. Despite a lower infection rate in the A-C group, neither hospital nor pharmacy costs were significantly different compared with those in the G-C group.

Abdominal Injuries↗
PubMedDate not supplied

The bioavailability of injectable, amorphous form of aztreonam.

Amorphos injectable form of aztreonam (BIOKTAM) was prepared. It was shown that after intramuscular or intravenous administration there are not any considerable differences in the bioavailability of aztreonam from BIOKTAM and of the drug from AZACTAM.

Adult↗
PubMed1998

Aztreonam plus piperacillin--empiric treatment of neutropenic fever in gynecology-oncology patients receiving cisplatin-based chemotherapy.

Antibiotic therapy must be instituted promptly and on an empiric basis in neutropenic patients. We evaluated the efficacy of a combined antibiotic regimen of monobactam (aztreonam) and antipseudomonal penicillin (piperacillin) in treating neutropenic fever episodes in gynecologic-oncology patients receiving cisplatin-based chemotherapy. A retrospective analysis of response to this regimen was performed. The rationale of this combination is the lack of nephrotoxicity and ototoxicity in patients who are or were previously treated with other nephrotoxic/ototoxic agents like cisplatin. A total of 19 courses of this regimen was administered to 13 patients with neutropenic fever following a complete fever work-up. Aztreonam (1-2gr q8h) plus piperacillin (4gr q8h) were administered intravenously for 6-8 days. Blood cultures were positive in four febrile episodes, and urine cultures were positive in seven. Gram negative organisms accounted for all positive cultures. The cultured organism showed in-vitro sensitivity to at least one of the drugs in all positive isolates. Clinical response with defervescence was noted during therapy in 18/19 courses (94.7%). Although the two drugs share a common bactericidal mechanism they were found to be highly active in this subgroup of patients. A double blind prospective evaluation of this empiric combination is warranted.

Adult↗
PubMedDate not supplied

High-performance liquid chromatography of alpha-amino acids and aztreonam on reversed phase columns with aqueous Cu2+ as eluent.

Parameters affecting the separation of amino acids on different RP-HPLC columns were studied. Six amino acids were separated on Zorbax TMS, Zorbax CN, Zorbax ODS and Zorbax C8, using 1.8 x 10(-3) M copper sulphate at pH 4.1 as aqueous mobile phase. The best separation was shown by Zorbax TMS followed by Zorbax CN. The column performance was maintained by serial washing after 6 h continuous work with aqueous 10(-4) M disodium edetate, 10(-4) N sulphuric acid, water and gradient elution with aqueous methanol. The separation mechanism was interpreted. The method was applied for separation and quantification of aztreonam and L-arginine in Azactam vials.

Amino Acids↗
PubMed1988

Dissemination in five French hospitals of Klebsiella pneumoniae serotype K25 harbouring a new transferable enzymatic resistance to third generation cephalosporins and aztreonam.

A strain of Klebsiella pneumoniae K25 resistant to newer beta-lactam drugs was isolated in clusters in five hospitals in the Paris area. The MICs of ceftazidime and aztreonam (greater than or equal to 128 mg/l) were higher than that of cefotaxime (16 mg/l) for the strain but, when measured in the presence of clavulanic acid, they were less than or equal to 1 mg/l. The donor strains and derivatives produced a beta-lactamase with a pI of 7.75-7.8 and hydrolysing activity against a wide spectrum of beta-lactams similar to that of SHV-2 and SHV-3, but with significant hydrolysis of ceftazidime. This new enzyme could be designated SHV-4.

Aztreonam↗